Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC(50)) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.
Molecular Weight:
323.325
CAS Number:
[1246200-39-4]
Formula:
C12H16N4O3 1/2C4H6O4
T202983
* VAT and and shipping costs not included. Errors and price changes excepted
